{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:36:40Z","timestamp":1793885800347,"version":"4.8.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1 R50 CA243707-01A1"],"award-info":[{"award-number":["1 R50 CA243707-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP121010"],"award-info":[{"award-number":["RP121010"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01266-0","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:33:00Z","timestamp":1745487180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-1055","authenticated-orcid":false,"given":"Hiroki","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hee","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea D.","family":"Bedoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muharrem","family":"Muftuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Basyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9424-5417","authenticated-orcid":false,"given":"Zoe","family":"Hirschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-9336","authenticated-orcid":false,"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-6368","authenticated-orcid":false,"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale Lee","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-1958","authenticated-orcid":false,"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100850","volume":"50","author":"E O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly E, Zeinabad HA, Szegezdi E. Hematopoietic versus leukemic stem cell quiescence: challenges and therapeutic opportunities. Blood Rev. 2021;50:100850.","journal-title":"Blood Rev"},{"key":"1266_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/leu.2017.300","volume":"32","author":"S Fujita","year":"2018","unstructured":"Fujita S, Honma D, Adachi N, Araki K, Takamatsu E, Katsumoto T, et al. Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. Leukemia. 2018;32:855\u201364.","journal-title":"Leukemia"},{"key":"1266_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.celrep.2018.06.110","volume":"24","author":"I Miller","year":"2018","unstructured":"Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, et al. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24:1105\u201312.e5.","journal-title":"Cell Rep"},{"key":"1266_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2023;141:1159\u201368.","journal-title":"Blood"},{"key":"1266_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/cas.13326","volume":"108","author":"D Honma","year":"2017","unstructured":"Honma D, Kanno O, Watanabe J, Kinoshita J, Hirasawa M, Nosaka E, et al. Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 2017;108:2069\u201378.","journal-title":"Cancer Sci"},{"key":"1266_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024;627:221\u20138.","journal-title":"Nature"},{"key":"1266_CR7","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1128\/MCB.17.10.5771","volume":"17","author":"ES Knudsen","year":"1997","unstructured":"Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol. 1997;17:5771\u201383.","journal-title":"Mol Cell Biol"},{"key":"1266_CR8","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","volume":"29","author":"M Yamagishi","year":"2019","unstructured":"Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29:2321\u201337.e7.","journal-title":"Cell Rep"},{"key":"1266_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/cas.13840","volume":"110","author":"M Nakagawa","year":"2019","unstructured":"Nakagawa M, Fujita S, Katsumoto T, Yamagata K, Ogawara Y, Hattori A, et al. Dual inhibition of enhancer of zeste homolog 1\/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma. Cancer Sci. 2019;110:194\u2013208.","journal-title":"Cancer Sci"},{"key":"1266_CR10","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Valemetostat tosilate: first approval. Drugs. 2022;82:1621\u20137.","journal-title":"Drugs"},{"key":"1266_CR11","doi-asserted-by":"publisher","first-page":"S311","DOI":"10.1016\/S2152-2650(24)01195-9","volume":"24","author":"HP Erba","year":"2024","unstructured":"Erba HP, Oluwole OO, Bixby D, Rampal RK, Fathi AT, Paliwal P, et al. AML-385 a phase 1 trial of valemetostat in patients with Relapsed or Refractory (R\/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL). Clin Lymphoma Myeloma Leuk. 2024;24:S311\u20132.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1266_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","volume":"125","author":"B Xu","year":"2015","unstructured":"Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2015;125:346\u201357.","journal-title":"Blood"},{"key":"1266_CR13","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28:1212\u201323.","journal-title":"Nat Med"},{"key":"1266_CR14","first-page":"747","volume":"33","author":"M Andreeff","year":"1990","unstructured":"Andreeff M, Tafuri A, Hegewisch-Becker S. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside. Haematol Blood Transfus. 1990;33:747\u201362.","journal-title":"Haematol Blood Transfus"},{"key":"1266_CR15","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/ajh.25943","volume":"95","author":"G Borthakur","year":"2020","unstructured":"Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, et al. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed\/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020;95:1296\u2013303.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01266-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:33:01Z","timestamp":1745487181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01266-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01266-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DH and ST are employees of Daiichi-Sankyo, Co., Ltd., NGD: Consultancy and Research Funding, Daiichi-Sankyo; OOO: Consultancy and advisory board for: Pfizer, Kite, Gilead, AbbVie, Janssen, TGR therapeutics, ADC, Novartis, Epizyme, Curio science, Nektar, Cargo, Caribou, Autolus, Bioheng, Allogene, BMS. Institution funding: Kite, Pfizer, Daichi Sankyo, Cargo, Caribou, Sana, Century Allogene, Abbvie. MA: Consultancy and Research Funding, Daiichi-Sankyo Inc.; Research Funding, Oxford Biomedical, Eterna Therapeutics Inc., Senti Bio, Sellas, Ellipses Pharma, Kintor Pharmaceutical Ltd., Syndax; Stocks or stock options, Eutropics, SentiBio, Eterna, Chimerix, Oncolyze; Honoraria, Eterna, SentiBio, Syndax, Glycomimetics, Aptose, Ona, Sellas, Boehringer-Ingelheim, Paraza, Roivant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"DS3201-A-U102 clinical trial and associated preclinical study were conducted in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki and were approved by the Independent Ethics Committee or Institutional Review Board (2016-1130). Written informed consent was obtained from all patients before study enrollment and sample collection. The animal study was performed following the guidelines approved by the Institutional Animal Care and Use Committees at MD Anderson Cancer Center (00001303-RN02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"76"}}